The approval and acceptance of monoclonal antibody biosimilars is necessary if the biosimilars market is to experience real growth.
Researchers are using current understanding of the lyophilization process to predict performance on many levels during both process development and manufacturing.
The targeted delivery of cytotoxic drugs using antibody drug conjugates would not be possible without effective linkers to connect and then release the key chemical and biological materials.
Automated sample handling, advanced glycan analysis and specially designed columns are helping biosimilar manufacturers speed up confirmation of the biosimilarity of their products.
Advances in instrumentation, software, and methodologies provide more information than ever on the higher-order structure of proteins.
With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.
Techniques to enable the design and formulation of stable, protein-based therapeutics.
Continuous countercurrent tangential chromatography (CCTC) is a column-free process that provides a scalable, disposable, and cost-saving alternative to column chromatography.
EMD Millipore and PharmaCell have entered into a collaboration to develop optimized large-scale expansion and harvest of HepaRG cells using bioreactor technology.